Galmed Pharmaceuticals Ltd.
$0.75
▲
6.93%
2026-04-21 07:06:02
galmedpharma.com
NCM: GLMD
Explore Galmed Pharmaceuticals Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.81 M
Current Price
$0.75
52W High / Low
$2.68 / $0.41
Stock P/E
—
Book Value
$3.49
Dividend Yield
—
ROCE
-38.45%
ROE
-64.21%
Face Value
—
EPS
$-2.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
0.47
Debt / Equity
0
Current Ratio
6.55
Quick Ratio
6.55
Forward P/E
-0.72
Price / Sales
—
Enterprise Value
$-13.28 M
EV / EBITDA
1.58
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 2. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
| 3. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 4. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 5. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 6. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 7. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.04 M | -2.1 M | -2.11 M | -1.26 M | -1.64 M | — |
| Net Profit | -4.82 M | -1.89 M | -2.5 M | -1.1 M | -3.21 M | — |
| EPS in Rs | -0.73 | -0.29 | -0.38 | -0.17 | -0.49 | -2.31 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -8.51 M | -6.28 M | -7.49 M | -17.65 M |
| Net Profit | -10.31 M | -7.52 M | -6.91 M | -17.87 M |
| EPS in Rs | -1.56 | -1.14 | -1.05 | -2.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 18.63 M | 18.5 M | 16.63 M | 16.56 M |
| Total Liabilities | 2.85 M | 2.17 M | 2.75 M | 3.14 M |
| Equity | 15.78 M | 16.33 M | 13.88 M | 13.42 M |
| Current Assets | 18.63 M | 16.12 M | 13.24 M | 14.72 M |
| Current Liabilities | 2.85 M | 2.17 M | 2.75 M | 3.09 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.32 M | -5.88 M | -6.14 M | -18.5 M |
| Investing CF | -3.38 M | -1.11 M | 0.8 M | 17.56 M |
| Financing CF | 9.03 M | 8.79 M | 6.18 M | 0.07 M |
| Free CF | -6.32 M | -5.88 M | -6.14 M | -18.5 M |
| Capex | — | — | — | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -37.14% | -8.75% | 61.31% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-30 | 1:0.0833333 |
| 2023-05-15 | 1:0.0666667 |